Understand the source comparison
Kisspeptin vs Oxytocin: Clinical Use Comparison
Primary Receptor Target GPR54 (KISS1R) in GnRH neurons OXTR in uterus, mammary glands, limbic system No receptor overlap. Mutually exclusive binding targets Mechanism of Action Stimulates GnRH release → triggers LH/FSH → drives gonadal hormone production Direc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Receptor Target
- GPR54 (KISS1R) in GnRH neurons
- OXTR in uterus, mammary glands, limbic system
- No receptor overlap. Mutually exclusive binding targets
- Mechanism of Action
- Stimulates GnRH release → triggers LH/FSH → drives gonadal hormone production
- Direct smooth muscle contraction (uterus), direct CNS modulation (limbic system)
- Kisspeptin operates upstream of hormones; oxytocin acts on end-organ tissues
- Reproductive Hormone Effect
- Increases LH 4.2-fold, testosterone 2.8-fold within 90 min (Phase 2 data)
- No effect on LH, FSH, testosterone, or estrogen levels
- Kisspeptin is the only peptide with documented gonadotropin-stimulating activity
- FDA-Approved Indications
- None (investigational status only)
- Labor induction, labor augmentation, postpartum hemorrhage control
- Oxytocin has established pharmaceutical approval; kisspeptin is pre-market
- Dosing Route
- Subcutaneous or IV bolus injection (research protocols)
- IV infusion (labor) or intranasal spray (neuropsychiatric trials)
- Route reflects target tissue. Systemic for kisspeptin, localized or CNS for oxytocin
- Half-Life
- Approximately 28 minutes (kisspeptin-54 isoform)
- 3–5 minutes (requires continuous infusion for labor)
- Kisspeptin's longer half-life allows single-dose efficacy; oxytocin requires drip